INDIVIOR INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: RBP-7000
Drug: Risperidone

First Posted Date: 2014-04-10

Last Posted Date: 2018-10-26

Lead Sponsor: Indivior Inc.

Target Recruit Count: 354

Registration Number: NCT02109562

Locations: 🇺🇸
Pillar Clinic Research, LLC, Dallas, Texas, United States
🇺🇸
Comprehensive Clinical Development - Cerritos, CA, Cerritos, California, United States
🇺🇸
Synergy Clinical Research of Escondido, Escondido, California, United States

and more 26 locations

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

Phase 2

Completed

Conditions: Opioid Use Disorder

Interventions: Drug: Buprenorphine
Drug: buprenorphine and naloxone
Drug: hydromorphone
Drug: placebo

First Posted Date: 2014-01-23

Last Posted Date: 2018-04-24

Lead Sponsor: Indivior Inc.

Target Recruit Count: 39

Registration Number: NCT02044094

Locations: 🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

Phase 4

Completed

Conditions: Opioid Dependence

Interventions: Drug: Zubsolv sublingual tablets
Drug: Suboxone Sublingual Film

First Posted Date: 2014-01-17

Last Posted Date: 2017-03-21

Lead Sponsor: Indivior Inc.

Target Recruit Count: 33

Registration Number: NCT02038790

Locations: 🇺🇸
Hill Top Research, St Petersburg, Florida, United States

A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse

Phase 2

Completed

Conditions: Cocaine Dependence
Opioid Related Disorders
Opioid Dependence

Interventions: Drug: RBP-8000 100 mg
Drug: Placebo
Drug: Cocaine
Drug: RBP-8000 200 mg

First Posted Date: 2013-05-03

Last Posted Date: 2016-09-23

Lead Sponsor: Indivior Inc.

Target Recruit Count: 40

Registration Number: NCT01846481

Locations: 🇺🇸
Vince and Associates Clinical Research, Overland Park,, Kansas, United States

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Phase 4

Completed

Conditions: Hepatic Impairment
Chronic Hepatitis C Infection With Hepatic Coma
Hepatic Failure

Interventions: Drug: 2.0mg Buprenorphine/0.5mg Naloxone
Drug: Promethazine

First Posted Date: 2013-05-03

Last Posted Date: 2016-10-24

Lead Sponsor: Indivior Inc.

Target Recruit Count: 43

Registration Number: NCT01846455

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Hialeah, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
American Research Corporation (ARC), San Antonio, Texas, United States

Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

Phase 2

Completed

Conditions: Opioid Related Disorder

Interventions: Drug: RBP-6000
Drug: Subutex

First Posted Date: 2012-11-30

Last Posted Date: 2018-02-23

Lead Sponsor: Indivior Inc.

Target Recruit Count: 124

Registration Number: NCT01738503

Locations: 🇺🇸
Vince and Associates Clinical Research, Overland Park, Kansas, United States

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Risperidone
Drug: RBP-7000

First Posted Date: 2012-09-03

Last Posted Date: 2018-10-23

Lead Sponsor: Indivior Inc.

Target Recruit Count: 45

Registration Number: NCT01677377

Locations: 🇺🇸
Woodland International Research Group, Inc., Little Rock, Alaska, United States
🇺🇸
Ocean View Psychiatric Health Facility, Long Beach, California, United States

Transfer of Subjects From Subutex/Suboxone to RBP-6300

Phase 2

Completed

Conditions: Opioid Related Disorder

Interventions: Drug: RBP-6300
Drug: Subutex®/Suboxone®
Drug: Placebo for RBP-6300
Drug: Placebo for Subutex®/Suboxone®

First Posted Date: 2012-04-20

Last Posted Date: 2017-01-20

Lead Sponsor: Indivior Inc.

Target Recruit Count: 143

Registration Number: NCT01582347

Locations: 🇦🇹
Dr. Lindenbauer, Linz, Austria
🇩🇪
Dr. Tietje, Bremen, Germany
🇨🇿
Dr. Vehak, Prague, Czech Republic

and more 12 locations

Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)

Phase 2

Completed

Conditions: Opioid Dependency

Interventions: Drug: Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
Drug: Buprenorphine hydrochloride fast dissolving tablet (FDT)

First Posted Date: 2010-02-25

Last Posted Date: 2023-04-11

Lead Sponsor: Indivior Inc.

Target Recruit Count: 52

Registration Number: NCT01075971

Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")

Phase 4

Completed

Conditions: Opioid Dependency

Interventions: Drug: Buprenorphine (Subutex)
Drug: Buprenorphine/naloxone (Suboxone)

First Posted Date: 2009-08-07

Last Posted Date: 2012-11-30

Lead Sponsor: Indivior Inc.

Target Recruit Count: 270

Registration Number: NCT00955162

Locations: 🇫🇷
Csst Antibes, Antibes, France
🇫🇷
Hopital Paul Guiraud, Bagneux, France
🇫🇷
Centre Carreire , CH Charles Perrens, Bordeaux, France

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy